NeuraLight

NeuraLight, co-founded by CEO Micha Breakstone and Edmund Ben-Ami, aims to improve the lives of patients with neurological disorders through digital neurological assessments and care. The company utilizes videos generated by standard smartphones or webcams, applying proprietary computer vision and deep learning algorithms to capture objective and sensitive digital markers, which help accelerate drug development and increase the success rate of new drugs. These digital endpoints can be used in all phases of clinical trials for treating a variety of neurological conditions, aiding in speeding up clinical trials and enhancing the likelihood of successful future treatments for Parkinson’s, Alzheimer’s, multiple sclerosis, and other neurodegenerative diseases. As the platform is device-agnostic, pharmaceutical companies can integrate and expand NeuraLight into clinical trials and remote settings, while also improving the patient experience.